Home›Trial›NCT07046585
NCT07046585RECRUITING

Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)

Study Summary

The FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC). Collected samples and data will be analyzed to evaluate the clinical performance of the Natera CRC Screening Test.

Conditions
Colo-rectal Cancer
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
NTRA
Natera Inc
Genetics Diagnostics
D48/100
Study Details
Enrollment25000 participants
Primary Completion—
Lead SponsorNatera, Inc.
Data Retrieved2026-04-11 04:23:02.260847+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 25,000 participants
Sponsor Catalyst Profile

Natera Inc (NTRA) is the sponsoring company for this trial. BiotechSign currently grades this company D (48/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NTRA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.